Measuring What Matters: Use of dd-cfDNA to Move Past Biopsy in Heart Transplant Care
Published 19 May 2026
At their industry symposium at ISHLT2026, Natera explored how emerging molecular tools are reshaping heart transplant surveillance beyond traditional histology. Experts highlighted evidence showing donor-derived cell-free DNA (dd-cfDNA) provides more objective, clinically relevant insights into graft health, with stronger correlation to outcomes like function and survival.
Through the support of Natera, this session is now available for you to view on demand.
Presenters:
- Philip F. Halloran, MD, PhD, University of Alberta | Edmonton, AB Canada
- Palak Shah, MD, MS, Inova Schar Heart and Vascular Institute | Falls Church, VA USA
- Gregory D. Lewis, MD, Massachusetts General Hospital | Boston, MA USA
The content of this recording was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.